ATAI (AtaiBeckley Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ATAI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-09 | ROBERT HERSHBERG | Director | MIXED | — | — |
| 2026-06-29 | Gerd Kochendoerfer | Chief Operating Officer | MIXED | — | — |
| 2026-06-29 | Kevin James Craig | Chief Medical Officer | MIXED | — | — |
| 2026-06-08 | Christian Angermayer | Director | A | — | — |
| 2026-06-08 | Amir H Kalali | Director | A | — | — |
| 2026-06-08 | Scott Braunstein | Director | A | — | — |
| 2026-06-08 | Andrea Heslin Smiley | Director | A | — | — |
| 2026-06-08 | SABRINA MARTUCCI JOHNSON | Director | A | — | — |
| 2026-06-08 | ROBERT HERSHBERG | Director | A | — | — |
| 2026-06-08 | John Francis Hoffman | Director | A | — | — |
| 2026-06-08 | Laurent Fischer | Director | A | — | — |
| 2026-04-22 | Kevin James Craig | Chief Medical Officer | MIXED | — | — |
| 2026-04-10 | Apeiron Investment Group Ltd. | 10%+ Owner | M | — | — |
| 2025-11-26 | Cosmo Feilding-Mellen | Director | MIXED | — | — |
| 2025-11-06 | Scott Braunstein | Director | A | — | — |
| 2025-11-06 | Cosmo Feilding-Mellen | Director | A | — | — |
| 2025-11-06 | ROBERT HERSHBERG | Director | A | — | — |
| 2025-10-03 | Christopher Ryan Cave Barrett | See Remarks | A | — | — |
| 2025-10-02 | Christian Angermayer | Director | C | — | — |
| 2025-08-18 | Apeiron Investment Group Ltd. | 10%+ Owner | Buy | — | — |
| 2025-08-15 | Srinivas Rao | See Remarks | A | — | — |
| 2025-06-27 | Scott Braunstein | Director | A | — | — |
| 2025-06-27 | Andrea Heslin Smiley | Director | A | — | — |
| 2025-06-27 | Amir H Kalali | Director | A | — | — |
| 2025-06-27 | Laurent Fischer | Director | A | — | — |
| 2025-06-27 | Christian Angermayer | Director | A | — | — |
| 2025-06-27 | SABRINA MARTUCCI JOHNSON | Director | A | — | — |
| 2025-06-27 | John Francis Hoffman | Director | A | — | — |
| 2025-06-04 | Christian Angermayer | Director | A | — | — |
| 2025-03-24 | Srinivas Rao | See Remarks | Sell | — | — |
| 2025-03-24 | Sahil Kirpekar | Chief Business Officer | Sell | — | — |
| 2025-03-24 | Anne Nagengast Johnson | Chief Financial Officer | Sell | — | — |
| 2025-03-24 | Glenn Frank Short | Chief Scientific Officer | Sell | — | — |
| 2025-03-24 | Apeiron Investment Group Ltd. | 10%+ Owner | Buy | — | — |
| 2025-03-24 | Kevin James Craig | Chief Medical Officer | Sell | — | — |
| 2025-03-19 | Anne Nagengast Johnson | Chief Financial Officer | M | — | — |
| 2025-03-19 | Kevin James Craig | Chief Medical Officer | M | — | — |
| 2025-03-19 | Srinivas Rao | See Remarks | M | — | — |
| 2025-03-19 | Glenn Frank Short | Chief Scientific Officer | M | — | — |
| 2025-03-19 | Sahil Kirpekar | Chief Business Officer | M | — | — |
| 2025-03-06 | Glenn Frank Short | Chief Scientific Officer | A | — | — |
| 2025-03-06 | Kevin James Craig | Chief Medical Officer | A | — | — |
| 2025-03-05 | Anne Nagengast Johnson | Chief Financial Officer | A | — | — |
| 2025-02-19 | Christian Angermayer | Director | Buy | — | — |
| 2025-01-10 | Srinivas Rao | See Remarks | A | — | — |
| 2025-01-03 | Gerd Kochendoerfer | Chief Operating Officer | A | — | — |
| 2024-10-04 | Christian Angermayer | Director | MIXED | — | — |
| 2024-10-04 | Srinivas Rao | See Remarks | MIXED | — | — |
| 2024-10-04 | Anne Nagengast Johnson | Chief Financial Officer | MIXED | — | — |
| 2024-10-04 | Florian Brand | See Remarks | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 53,412,414 | — |
| — | 10%+ Owner | 20,185,200 | — |
| — | Director | 7,702,990 | — |
| — | 10%+ Owner | 2,358,534 | — |
| — | Director | 524,308 | — |
| — | See Remarks | 331,030 | — |
| — | See Remarks | 216,442 | — |
| — | Chief Financial Officer | 140,045 | — |
| — | Chief Business Officer | 115,636 | — |
| — | Director | 100,000 | — |
| — | Chief Operating Officer | 50,000 | — |
| — | Chief Scientific Officer | 42,333 | — |
| — | Chief Medical Officer | 8,437 | — |
| — | Director | 4,666 | — |
| — | Director | 4,666 | — |
| — | Director | 4,666 | — |
| — | Chief Financial Officer | 4,666 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ATAI quote page; the site-wide leaderboard is on the insider transactions hub.